ToolsCalculators
Gillmore Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Two-biomarker prognostic stage for ATTR cardiac amyloidosis (wild-type or hereditary).
Gillmore Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
NT-proBNP
ng/L
eGFR
mL/min/1.73m2
Complete the fields above to see the result.
When to use
- Prognostic staging of confirmed ATTR cardiac amyloidosis (wild-type or hereditary) at diagnosis or before starting disease-modifying therapy.
Formula
Stage I: NT-proBNP <=3000 ng/L and eGFR >=45 mL/min. Stage III: NT-proBNP >3000 ng/L and eGFR <45 mL/min. Stage II: either value abnormal but not both.
Pearls and pitfalls
- Validated in both ATTRwt and hereditary ATTRv cardiomyopathy, and externally validated in a French cohort.
- Simpler than the Grogan (Mayo) system, which uses troponin T and NT-proBNP instead of renal function.